Clinical Trial Update: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol [Phase 1, Phase 2]

View source ↗

Summary

A master protocol trial evaluating Isatuximab in combination with novel agents for relapsed/refractory multiple myeloma is in Phase 1/2 and currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Isatuximab (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma Refractory | Phase 1, Phase 2 | Status: RECRUITING